Back to search results

A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Advanced Solid Tumors

Abroad (travel likely)RecruitingPHASE1

Conditions

Locally Advanced or Metastatic Solid Tumors

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Calvary Mater Newcastle, Sydney, New South Wales, Australia

    Contact: Study coordinator (Janine Lomabard, MD) · Janine.Lombard@calvarymater.org.au

  • Pindara Private Hospital, Benowa, Queensland, Australia

    Contact: Study coordinator (Mark Page, PhD) · HollandT@ramsayhealth.com.au · +61 7 5588 9040

  • Southern Oncology Clinical Research Unit, Bedford Park, South Australia, Australia

  • Peninsula & South Eastern Haematology and Oncology Group, Frankston, Victoria, Australia

    Contact: Study coordinator (Albert Goikhman, PhD) · ag@paso.com.au · 03 9113 1307

  • One Clinical Research Pty Ltd, Mount Pleasant, Western Australia, Australia

    NA NA · management@oneclinicalresearch.com.au

  • Chongqing Cancer Hospital, Chongqing, Chongqing Municipality, China

  • Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China

Study leads

  • Ganessan Kichenadasse, MD

    Principal Investigator

    Southern Oncology Clinical Research Unit

  • Yi-Long Wu, PhD

    Principal Investigator

    Guangdong Provincial People's Hospital

  • Qing Zhou

    Principal Investigator

    Guangdong Provincial People's Hospital

View source on ClinicalTrials.gov(opens in a new tab)